This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2026
Grand Nikko Tokyo DaibaTokyo

Paymaan Jafar-nejad, MD
Executive Director, Neurology Research at Ionis Pharmaceuticals
Speaker

Profile

Paymaan Jafar-Nejad, MD, is a scientific leader in RNA therapeutics and currently serves as Executive Director at Ionis Pharmaceuticals, Inc., a pioneering biotechnology company in RNA-targeted drug discovery and development. He brings more than two decades of experience in neuroscience and RNA biology, including over a decade focused on oligonucleotide therapeutics, and has contributed to a substantial body of scientific publications in the field.

Dr. Jafar-Nejad earned his medical degree from Tehran University of Medical Sciences and completed postdoctoral training in Dr. Huda Zoghbi’s laboratory at Baylor College of Medicine, where he investigated mechanisms of neurodegeneration. At Ionis, he has led research programs in neurology and rare diseases, advancing RNA-based therapies into clinical trials for ALS, Angelman syndrome, genetic epileptic encephalopathies, and related disorders. In recognition of this work, he and his colleagues received the 2023 Lalji & Family ALS Endowed Award for Innovative Healing from the Healey & AMG Center at Massachusetts General Hospital.

Agenda Sessions

  • Harnessing VHH ‘Nanobody’ As a Delivery System to Cross the BBB

    12:00pm

At this event